CRF Health’s TrialMax Touch® Selected by Leading Specialty Pharmaceutical Company for Pediatric Rare Disease Phase II Study
Plymouth Meeting, PA-November 14, 2017-CRF Health, a global provider of patient-centered eSource technology and service solutions for the life sciences industry, has been selected by a specialty pharmaceutical company for its latest pediatric rare disease Phase II study.
The trial will utilize CRF Health’s TrialStudio®, TrialMax®, and TrialManager® eCOA solutions to collect quality of life readings and capture compliance data for caregivers (predominantly parents) throughout the study. Specifically, the TrialMax Touch® handheld mobile devices will be used as a practical solution. This will alleviate the burden of data entry, easily integrating into the lives of the caregivers who will be administering twice weekly injections. For this study multi-users will have access to the platform for one subject, enabling two caregivers to enter data. Expected to start screening patients before the end of 2017, this pioneering clinical trial will cover 50 sites and include 150 patients in 15 countries over two and a half years.
Common challenges in rare disease trials include patient recruitment, capturing meaningful, comparative data, patient engagement and retention, and logistics and scale. Due to the small number of patients enrolled in this rare disease study, ensuring enough data is collected to make actionable decisions is more challenging and significant effort is needed to make every data point count. Mobile, intuitive and easy-to-use, TrialMax Touch fits into subjects’ real lives to fuel high compliance and complete data.
Rachel Wyllie, CEO, comments, “We are proud to support this company’s commitment to offering physicians and patients new treatment alternatives in areas of unmet medical need. CRF Health is providing a unique solution for this study in addition to our traditional eCOA offering with our class 1 medical device utilized as a medication reminder and log, which is something not all eCOA providers can deliver. Our design process, powered by TrialStudio®, was pivotal in securing this contract. It provides a collaborative, interactive, and agile approach to the entire process and we’re delighted to be involved in a trial that will offer a significant amount of value to a rare disease that has very limited treatment options.”
For further information on CRF Health, please visit www.crfhealth.com
About CRF Health
CRF Health is a provider of patient-centered eSource and telemedicine solutions for the life sciences industry. With experience in more than 800 clinical trials, over 100 languages and across 74 countries, CRF Health’s TrialMax® platform consistently demonstrates the industry’s highest data accuracy, patient and site compliance, and patient retention. Its recent acquisition of mHealth provider Entra Health, has allowed CRF Health to extend the connectivity of its existing technology to now include cloud-based remote patient monitoring, telehealth, data exchange and analytics.
CRF Health’s eSource solutions improve trial engagement by making the patient the center of the healthcare and clinical trial process. The integrated TrialMax platform includes eCOA solutions for collecting PROs (Patient Reported Outcomes), ObsROs (Observer Reported Outcomes), ClinROs (Clinician or Rater Reported Outcomes), and PerfOs (Performance Outcomes), and features TrialConsent™, an electronic solution for collecting informed consent in clinical trials.
Contact: media@crfhealth.com, +1 267.498.2350
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
